Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results44

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results32

Views

Views
January 20255
February 20253
March 202515
April 20252
May 20252
June 20254
July 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States7
United Kingdom5
Lithuania2
Brazil1
Spain1
Guatemala1
 

Top cities views

Views
Council Bluffs1
Fort Collins1
Guatemala City1
Nova Serrana1
Virginia Water1